Cabazitaxel

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1340 publications

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

Journal: JAMA network open

Published: January 16, 2026

Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.

Comparative incidence of peripheral neuropathy associated with taxane chemotherapy in patients with breast cancer: A network meta-analysis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: December 15, 2025

Cabazitaxel Sustained-Release Nanoparticles Treat Spinal Cord Injury through Inhibiting Fibrin Deposition and Improving the Microenvironment.

Cabazitaxel Sustained-Release Nanoparticles Treat Spinal Cord Injury through Inhibiting Fibrin Deposition and Improving the Microenvironment.

Journal: Biomacromolecules

Published: November 14, 2025

Obesogenic Dysregulation of Human Periprostatic Adipose Tissue Promotes the Viability of Prostate Cells and Reduces Their Sensitivity to Docetaxel and Cabazitaxel.

Obesogenic Dysregulation of Human Periprostatic Adipose Tissue Promotes the Viability of Prostate Cells and Reduces Their Sensitivity to Docetaxel and Cabazitaxel.

Journal: Medical sciences (Basel, Switzerland)

Published: November 05, 2025

Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer.

Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer.

Journal: JCI insight

Published: November 04, 2025

Prediction of cabazitaxel-induced severe neutropenia based on dose-to-albumin ratio and evaluation of clinical utility.

Prediction of cabazitaxel-induced severe neutropenia based on dose-to-albumin ratio and evaluation of clinical utility.

Journal: Die Pharmazie

Published: October 28, 2025

A Rare Presentation of Metastatic Prostate Cancer With Recurrent Malignant Ascites: A Case Report and Literature Review.

A Rare Presentation of Metastatic Prostate Cancer With Recurrent Malignant Ascites: A Case Report and Literature Review.

Journal: Cureus

Published: October 06, 2025

Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting.

Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting.

Journal: Oncology and therapy

Published: September 11, 2025

A Nanodrug Self-Assembled from a Redox-Responsive Cabazitaxel-Zosuquidar Conjugate and DSPE-PEG2k Reverses Multidrug Resistance in Nonsmall Cell Lung Cancer.

A Nanodrug Self-Assembled from a Redox-Responsive Cabazitaxel-Zosuquidar Conjugate and DSPE-PEG2k Reverses Multidrug Resistance in Nonsmall Cell Lung Cancer.

Journal: ACS applied bio materials

Published: September 03, 2025

Editorial Comment on "Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis".

Editorial Comment on "Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis".

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: September 01, 2025

Use of nanoemulsion for co-delivery of silibinin and cabazitaxel for prostate cancer treatment.

Use of nanoemulsion for co-delivery of silibinin and cabazitaxel for prostate cancer treatment.

Journal: Drug development and industrial pharmacy

Published: August 25, 2025

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for cabazitaxel.

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for cabazitaxel.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: August 24, 2025

Showing 1-12 of 1,340

Last Updated: 02/24/2026